Cargando…

Evidence of CYP3A Allosterism In Vivo: Analysis of Fluconazole and Midazolam Interaction

The allosteric effect of fluconazole (effector) on the formation of 1’-hydroxymidazolam (1’-OH-MDZ) and 4-hydroxymidazolam (4-OH-MDZ) from the CYP3A4/5 substrate, midazolam (MDZ), was examined in healthy volunteers. Following pre-treatment of fluconazole, AUC(4-OH)/AUC(MDZ) increased 35–62%, while A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Jing, Atkins, William M., Isoherranen, Nina, Paine, Mary F., Thummel, Kenneth E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830930/ https://www.ncbi.nlm.nih.gov/pubmed/22048224 http://dx.doi.org/10.1038/clpt.2011.178

Ejemplares similares

Fluoxetine and norfluoxetine mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19 and CYP3A4
por: Sager, Jennifer E, et al.
Publicado: (2014)

An Integrative Approach to Elucidate Mechanisms Underlying the Pharmacokinetic Goldenseal-Midazolam Interaction: Application of In Vitro Assays and Physiologically Based Pharmacokinetic Models to Understand Clinical Observations
por: Nguyen, James T., et al.
Publicado: (2023)

CRABPs Alter all-trans-Retinoic Acid Metabolism by CYP26A1 via Protein-Protein Interactions
por: Yabut, King Clyde B., et al.
Publicado: (2022)

Midazolam as a Probe for Heterotropic Drug-Drug Interactions Mediated by CYP3A4
por: Denisov, Ilia G., et al.
Publicado: (2022)

Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity
por: Wiebe, Sabrina T., et al.
Publicado: (2020)

Inhibition of CYP3A-mediated Midazolam Metabolism by Kaempferia Parviflora
por: Kashiwabuchi, Yumika, et al.
Publicado: (2022)

Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants
por: Salerno, Sara N., et al.
Publicado: (2020)

Inhibitory effects of Triphala on CYP isoforms in vitro and its pharmacokinetic interactions with phenacetin and midazolam in rats
por: Nontakham, Jannarin, et al.
Publicado: (2022)

Amenamevir: Studies of Potential CYP3A‐Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers
por: Adeloye, Temitope, et al.
Publicado: (2018)

Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats
por: Lou, Yutao, et al.
Publicado: (2023)

Differences of Atomic-Level Interactions between Midazolam and Two CYP Isoforms 3A4 and 3A5
por: Liu, Shuhui, et al.
Publicado: (2023)

Scaling in vitro activity of CYP3A7 suggests human fetal livers do not clear retinoic acid entering from maternal circulation
por: Topletz, Ariel R., et al.
Publicado: (2019)

Translating Kratom-Drug Interactions: From Bedside to Bench and Back
por: Tanna, Rakshit S., et al.
Publicado: (2023)

Successful treatment of hypercalcaemia associated with a CYP24A1 mutation with fluconazole
por: Sayers, Judith, et al.
Publicado: (2015)

Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1‐OH‐midazolam in morbidly obese and weight loss surgery patients
por: Brill, MJE, et al.
Publicado: (2015)

Pharmacokinetic Evaluation of CYP3A4‐Mediated Drug‐Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults
por: Townsend, Robert, et al.
Publicado: (2016)

Adapting regulatory drug‐drug interaction guidance to design clinical pharmacokinetic natural product‐drug interaction studies: A NaPDI Center recommended approach
por: Cox, Emily J., et al.
Publicado: (2021)

Coexistent CYP24A1 and PHEX Gene Mutations With Hypervitaminosis D Plus Hypercalcemia Treated With Fluconazole
por: Bawden, David, et al.
Publicado: (2021)

Analogosedation during flexible bronchoscopy using a combination of midazolam, propofol and fentanyl – A retrospective analysis
por: Müller, Tobias, et al.
Publicado: (2017)

A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children
por: Brussee, Janneke M., et al.
Publicado: (2019)

Tacrolimus pharmacokinetics are influenced by CYP3A5, age, and concomitant fluconazole in pediatric kidney transplant patients
por: Alghamdi, Alaa, et al.
Publicado: (2023)

Physiologically‐Based Pharmacokinetic Models for CYP1A2 Drug–Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam
por: Britz, Hannah, et al.
Publicado: (2019)

Inhibitory Effects of Baicalin on the Expression and Activity of CYP3A Induce the Pharmacokinetic Changes of Midazolam in Rats
por: Tian, Xin, et al.
Publicado: (2013)

First‐Pass CYP3A‐Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates
por: Brussee, Janneke M., et al.
Publicado: (2018)

Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects
por: Gardin, Anne, et al.
Publicado: (2018)

Pregnancy related hormones increase CYP3A mediated buprenorphine metabolism in human hepatocytes: a comparison to CYP3A substrates nifedipine and midazolam
por: Fashe, Muluneh M., et al.
Publicado: (2023)

Sex and Age Influence on Association of CYP450 Polymorphism with Midazolam Levels in Critically Ill Children
por: Flores-Pérez, Carmen, et al.
Publicado: (2022)

Fluconazole–malonic acid (1/1)
por: Kastelic, Jože, et al.
Publicado: (2013)

The effect of piperine on midazolam plasma concentration in healthy volunteers, a research on the CYP3A-involving metabolism
por: Rezaee, Mohammad Mahdi, et al.
Publicado: (2014)

The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam
por: Wiesinger, Herbert, et al.
Publicado: (2020)

In Vivo Functional Effects of CYP2C9 M1L, a Novel and Common Variant in the Yup’ik Alaska Native Population
por: Henderson, Lindsay M., et al.
Publicado: (2021)

In vitro and in vivo anti-Candida activity of citral in combination with fluconazole
por: Miranda-Cadena, Katherine, et al.
Publicado: (2022)

PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin
por: Hanke, Nina, et al.
Publicado: (2018)

Vitamin D3 Is Transformed into 1,25(OH)(2)D(3) by Triggering CYP3A11(CYP3A4) Activity and Hydrolyzing Midazolam
por: Zhu, Hanfei, et al.
Publicado: (2019)

Time-dependent inhibition of CYP3A4-mediated midazolam metabolism by macrolide antibiotics in CYP3A4 genetic variants: Comparison with testosterone metabolism
por: Akiyoshi, Takeshi, et al.
Publicado: (2021)

The Synergism of the Small Molecule ENOblock and Fluconazole Against Fluconazole-Resistant Candida albicans
por: Li, Liping, et al.
Publicado: (2019)

Fluconazole (Diflucan®)
por: Hollier, Lisa M., et al.
Publicado: (1995)

Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole
por: Chen, Chiung-Kuang, et al.
Publicado: (2010)

Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content
por: Shirasaka, Y, et al.
Publicado: (2016)

Fluconazole Resistance and Virulence in In Vitro Induced-Fluconazole Resistant Strains and in Clinical Fluconazole Resistant Strain of Cryptococcus deuterogattii
por: Bertout, Sébastien, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ikg5iq2uf7avbad18ccu1vngrr